- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06808477
Um estudo do BBT001 em voluntários saudáveis (HVs) e em pacientes adultos com dermatite atópica (DA)
Um estudo randomizado, cego, controlado por placebo, de doses de ascendência única e múltipla para avaliar a segurança, tolerabilidade, farmacocinética, imunogenicidade, farmacodinâmica e atividade clínica de BBT001 em HVs e pacientes com DA
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This study a is a randomized, double-blinded, placebo-controlled single (SAD) and multiple-ascending dose (MAD) study to evaluate safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and exploratory clinical activity of BBT001 in healthy volunteers (HVs) and in adult patients with atopic dermatitis. BBT001 is a drug candidate being developed for the treatment of atopic dermatitis.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Lisa Li
- Número de telefone: +1 617-848-6188
- E-mail: Lisa.Li@bambusatx.com
Locais de estudo
-
-
Western Australia
-
Fremantle, Western Australia, Austrália, 6160
- Recrutamento
- Fremantle Dermatology
-
Perth, Western Australia, Austrália, 6009
- Concluído
- Linear Clinical Research
-
-
-
-
California
-
Irvine, California, Estados Unidos, 92614
- Recrutamento
- First OC Dermatology
-
-
New York
-
New York, New York, Estados Unidos, 10128
- Recrutamento
- OptiSkin Medical
-
The Bronx, New York, Estados Unidos, 10455
- Recrutamento
- Equity Medical, LLC
-
-
-
-
-
Christchurch, Nova Zelândia
- Recrutamento
- Optimal Clinical Trials Ltd - Christchurch
-
Upper Hutt, Nova Zelândia, 5018
- Recrutamento
- Pacific Clinical Research Network (PCRN) Wellington
-
Contato:
- Tim Humphrey
-
-
Auckland
-
Grafton, Auckland, Nova Zelândia, 1010
- Recrutamento
- Optimal Clinical Trials Central Auckland
-
Contato:
- Arna Letica
-
Otahuhu, Auckland, Nova Zelândia, 2025
- Retirado
- Aotearoa Clinical Trials
-
Takapuna, Auckland, Nova Zelândia, 0622
- Recrutamento
- Pacific Clinical Research Network (PCRN) - Auckland
-
Contato:
- Paul Hamilton
-
-
-
-
-
Lodz, Polônia, 91-347
- Recrutamento
- Wojewódzki Specjalistyczny Szpital im. Dr. Wł. Biegańskiego w Łodzi
-
Rzeszów, Polônia, 35-055
- Recrutamento
- Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie
-
Warsaw, Polônia, 02-507
- Recrutamento
- Państwowy Instytut Medyczny MSWiA
-
Wroclaw, Polônia, 50-566
- Recrutamento
- Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak Spółka Partnerska
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria
- Negative pregnancy tests for women of childbearing potential.
- Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
- Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
- Adequate contraception use (for men and women of childbearing potential).
Key Inclusion Criteria (Parts A, B, and D)
- Age of 18-65 years.
- Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
- No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Parts C and E only)
- Age of 18-72 years.
- Body mass index ≥16 kg/m², weight capped at 125 kg.
- Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
- Moderate to severe atopic dermatitis
- Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
- Atopic lesions cover ≥10% of body surface area (BSA)
- Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Key Exclusion Criteria
- Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
- History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
- Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
- Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
- Abnormal Electrocardiogram (ECG) findings
- History of drug/alcohol abuse in the past 2 years.
- Donated >500mL blood within 2 months of screening.
- History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria (Parts A, B, and D only)
1. History of atopic dermatitis
Key Exclusion Criteria (Parts C and E only)
- Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
- Receipt of immunoglobulin or blood products within 30 days.
- Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
- Chronic pruritus from conditions other than atopic dermatitis.
- Acute/treated infections or chronic skin infections.
- Current use of sedating antihistamines or corticosteroids.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part A Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Experimental: Part B Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in healthy volunteers. |
BBT001 will be administered |
|
Experimental: Part C Multiple Ascending Dose BBT001
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Comparador de Placebo: Part A Single Ascending Dose Placebo
A single dose of Placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Comparador de Placebo: Part B Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in healthy volunteers. |
Placebo will be administered |
|
Comparador de Placebo: Part C Multiple Ascending Dose Placebo
Multiple doses of Placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Comparador Ativo: Part D Single Ascending Dose BBT001
A single dose of BBT001 will be administered in healthy volunteers |
BBT001 will be administered |
|
Comparador de Placebo: Part D Single Ascending Dose Placebo
A single dose of placebo will be administered in healthy volunteers |
Placebo will be administered |
|
Comparador Ativo: Part E Multiple Ascending Dose BBT001 - Dose Level 1
Multiple doses of BBT001 will be administered in patients with atopic dermatitis. |
BBT001 will be administered |
|
Comparador de Placebo: Part E Multiple Ascending Dose Placebo
Multiple doses of placebo will be administered in patients with atopic dermatitis. |
Placebo will be administered |
|
Comparador Ativo: Part E Multiple Ascending Dose BBT001 - Dose Level 2
Multiple doses of BBT001 will be administered in patients with atopic dermatitis |
BBT001 will be administered |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with adverse events following single and multiple administration of BBT001
Prazo: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Incidence, relatedness, and severity of adverse events graded per NCI CTCAE v5.0. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in serum blood parameters
Prazo: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Laboratory assessments include hematology, blood chemistry and coagulation test |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in vital sign measurements following treatment administration.
Prazo: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Blood pressure and heart rate will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in physical examination following treatment administration.
Prazo: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Physical examination will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
|
Number of participants with change in 12-lead ECG readings
Prazo: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
12-lead ECG will be assessed. |
Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pharmacokinetics parameters - maximum observed Concentration (Cmax)
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Maximum observed concentration of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Time for maximum observed Concentration (Tmax)
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum PK Tmax will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Area under the curve (AUC)
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Area under the curve of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Volume of distribution (Vz)
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Volume of distribution of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Total clearance (CL)
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Total clearance of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
Pharmacokinetics parameters - Elimination Half-life (t1/2).
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Elimination half-life of the study drug in serum will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
|
The immunogenicity of BBT001 is measured as the number and percentage of subjects who develop Anti-Drug Antibodies (ADA).
Prazo: At specified timepoints pre-dose and up to 169 days post first dose administration
|
Serum Anti-Drug Antibodies will be analyzed for all subjects |
At specified timepoints pre-dose and up to 169 days post first dose administration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Lisa Li, Bambusa Therapeutics, Inc.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Genéticas, Congênitas
- Doenças do sistema imunológico
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Doenças de pele
- Doenças de Pele Genéticas
- Doenças de Pele, Eczematosas
- Dermatite
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças da Pele e do Tecido Conjuntivo
- Dermatite Atópica
Outros números de identificação do estudo
- BBT001-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .